Studies abrocitinib in adults with moderate to severe atopic dermatitis
Observes how abrocitinib tablets work and feel for adults with long-lasting eczema.
Plain-language title generated from the registry record
Registry title: A Study to Learn About Abrocitinib in Adult Patients With Moderate to Severe Atopic Dermatitis.
Key facts
- Where
- Amiens, Besançon, Bezannes, Bordeaux, Brest, Caen, Calais, Chalon-sur-Saône, Clermont-Ferrand, Créteil, Dijon, Levallois-Perret, Lille, Martigues, Montpellier, Mulhouse, Nantes, Paris, Pierre-Bénite, Rennes, Romans-sur-Isère, Rouen, Saint-Germain-en-Laye, Saint-Mandé, Toulouse, Valenciennes, and Vandœuvre-lès-Nancy, FranceSee the 30 sites
Where in France
- CHU Amiens Picardie site NordAmiens, FranceTaking people
- CHU Besancon - Hopital Jean MinjozBesançon, FranceTaking people
- Polyclinique Reims BezannesBezannes, FranceTaking people
- CHU Bordeaux Hopital Saint AndreBordeaux, FranceTaking people
- Chu Brest Hopital MorvanBrest, FranceTaking people
- CHU de CAENCaen, FranceTaking people
- CH de CalaisCalais, FranceTaking people
- CH William MoreyChalon-sur-Saône, FranceTaking people
- CHU Clermont Ferrand - Hôpital Gabriel MontpiedClermont-Ferrand, FranceTaking people
- CHU EstaingClermont-Ferrand, FranceTaking people
- Hopital Henri MondorCréteil, FranceTaking people
- CHU DijonDijon, FranceTaking people
- Hôpital Franco-BritanniqueLevallois-Perret, FranceTaking people
- Hopital Claude HuriezLille, FranceTaking people
- CH de MartiguesMartigues, FranceTaking people
- CHU MontpellierMontpellier, FranceTaking people
- Hôpital Emile MullerMulhouse, FranceTaking people
- Hopital Hotel DieuNantes, FranceTaking people
- Hôpital CochinParis, FranceTaking people
- Hopital Saint Louis (APHP) - Service Hematologic SeniorParis, FranceTaking people
- Hôpital TenonParis, FranceTaking people
- CHU Lyon SudPierre-Bénite, FranceTaking people
- Hôpital PontchaillouRennes, FranceTaking people
- Ch de Romans Sur IsereRomans-sur-Isère, FranceTaking people
- Hôpital Charles NicolleRouen, FranceTaking people
- Chi Poissy Saint Germain En LayeSaint-Germain-en-Laye, FranceTaking people
- Hôpital BéginSaint-Mandé, FranceTaking people
- Hopital LarreyToulouse, FranceTaking people
- CH de ValenciennesValenciennes, FranceTaking people
- CHU NancyVandœuvre-lès-Nancy, FranceTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Pfizer
- Trial code
- NCT05689151
- Record updated
- 7 July 2026
- Original description
The purpose of this study is to learn about the safety and effects of Abrocitinib in the real-life clinical setting given for the treatment of moderate to severe atopic dermatitis. Atopic dermatitis, or AD, is a long-lasting disease that causes inflammation, redness, and irritation of the skin.Read full original descriptionShow less
Treating Atopic Dermatitis With Abrocitinib and Its Impact in Real Life: An Observational Cohort Study To Describe the Effectiveness of Abrocitinib in Patients With Moderate-to-Severe Atopic Dermatitis.
The purpose of this study is to learn about the safety and effects of Abrocitinib in the real-life clinical setting given for the treatment of moderate to severe atopic dermatitis. Atopic dermatitis, or AD, is a long-lasting disease that causes inflammation, redness, and irritation of the skin.
This study is seeking participant who are older than 18 years with moderate-to-severe chronic AD. Participants must have no underlying medical conditions that prevent them from taking Abrocitinib.
All participants in this study will receive Abrocitinib as a tablet once daily. They can take Abrocitinib and use medicated topical treatment for AD at the same time.
We will examine the experiences of patients receiving the study medicine. This will help us determine if the study medicine is safe and helps in treating AD.
Participants will take part in this study for 24 months. During this time, they will visit the study clinic about 5 times (about 1 time every 4 to 6 months).
Inclusion: Patients older than 18 years of age at inclusion; Patients with clinical diagnosis of moderate-to-severe chronic atopic dermatitis (also referred to as atopic eczema) at inclusion according to the investigator and eligible for abrocitinib according to its marketing approval; Patients that have been informed of the study procedures and have signed the consent.
Exclusion: Patients for whom abrocitinib is contraindicated; Patients unable to follow and respect the study procedures and judged inapt to respond to the questions required for the study due to linguistical, psychological, social, or geographical reasons; Patients not affiliated to the French social security system; Patients deprived of liberty, under guardianship, or unable to provide oral consent; Patients participating in a clinical study assessing a medicinal treatment (patients can participate in registries and observatories).